A phase 2 study of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in patients (pts) with progressive metastatic castration-resistant prostate …

DP Petrylak, NJ Vogelzang, GS Chatta, MT Fleming… - 2015 - ascopubs.org
144 Background: PSMA is a validated target that is overexpressed selectively on prostate
cancer cells. PSMA ADC is a fully human IgG1 antibody conjugated to the microtubule …
被引用次数：23 相关文章

A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer …

DP Petrylak, DC Smith, LJ Appleman, MT Fleming… - 2014 - ascopubs.org
5023 Background: PSMA expression on prostate cancer cells provides a rationale for ADC
therapy. PSMA is a clinically validated target. PSMA ADC is a fully human antibody to PSMA …
被引用次数：26 相关文章

PSMA ADC monotherapy in patients with progressive metastatic castration‐resistant prostate cancer following abiraterone and/or enzalutamide: Efficacy and safety in …

DP Petrylak, NJ Vogelzang, K Chatta… - The …, 2020 - Wiley Online Library
Background Prostate‐specific membrane antigen (PSMA) is a well‐established therapeutic
and diagnostic target overexpressed in both primary and metastatic prostate cancers. PSMA …
被引用次数：72 相关文章 所有 5 个版本

A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer …

DP Petrylak, DC Smith, LJ Appleman, MT Fleming… - 2014 - ascopubs.org
83 Background: The abundant expression of prostate-specific membrane antigen (PSMA)
on prostate cancer cells provides a rationale for antibody therapy. PSMA antibody drug …
被引用次数：12 相关文章

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously …

AE Mega, DP Petrylak, P Kantoff, J Stephenson… - 2012 - ascopubs.org
4662 Background: The abundant expression of prostate specific membrane antigen (PSMA)
type II transmembrane glycoprotein on prostate cancer cells provides a rationale for …
被引用次数：6 相关文章

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in metastatic castration-resistant prostate cancer (mCRPC) previously …

DP Petrylak, PW Kantoff, AE Mega, NJ Vogelzang… - 2013 - ascopubs.org
119 Background: The abundant expression of prostate specific membrane antigen (PSMA)
on prostate cancer cells provides a rationale for antibody therapy. PSMA ADC, a fully human …
被引用次数：20 相关文章

Phase 1 study of PSMA ADC, an antibody‐drug conjugate targeting prostate‐specific membrane antigen, in chemotherapy‐refractory prostate cancer

DP Petrylak, P Kantoff, NJ Vogelzang, A Mega… - The …, 2019 - Wiley Online Library
Background Prostate‐specific membrane antigen (PSMA) is a well‐characterized target that
is overexpressed selectively on prostate cancer cells. PSMA antibody‐drug conjugate (ADC) …
被引用次数：67 相关文章 所有 4 个版本

MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide.

JS De Bono, MT Fleming, JSZ Wang, R Cathomas… - 2020 - ascopubs.org
99 Background: MEDI3726 is an ADC targeting PSMA. Once bound to PSMA and
internalized, the released pyrrolobenzodiazepine dimer toxin crosslinks DNA and triggers …
被引用次数：14 相关文章
[PDF] annalsofoncology.org

1804P APEX-01: first-in-human phase I/II study of ARX517 an anti-prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC) in patients (pts) with …

J Shen, R Pachynski, LT Nordquist, N Adra… - Annals of …, 2023 - annalsofoncology.org
Background ARX517 is a novel ADC composed of a fully humanized anti-PSMA mAb
conjugated to amberstatin-269, a potent tubulin inhibitor. ARX517 was designed to reduce …
被引用次数：5 相关文章

Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A phase I trial in taxane-refractory prostate cancer.

DP Petrylak, PW Kantoff, Y Rotshteyn… - Journal of Clinical …, 2011 - ascopubs.org
158 Background: The unique expression of PSMA type II transmembrane glycoprotein on
prostate cancer cells provides a potentially attractive target for antibody therapy. PSMA ADC …
被引用次数：15 相关文章 所有 3 个版本